Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Dogan, Yasar" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł:
Hepatoprotective effects of Tribulus terrestris, Ashwagandha and N-acetylcysteine on liver fibrosis in carbon tetrachloride-induced rats
Autorzy:
Altay, Derya
Dogan, Yasar
Orhan, Cemal
Tuzcu, Mehmet
Sahin, Nurhan
Ozercan, Ibrahim
Sahin, Kazım
Powiązania:
https://bibliotekanauki.pl/articles/895409.pdf
Data publikacji:
2019-10-30
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
N-acetylcysteine
carbon tetrachloride
liver fibrosis
Ashwagandha
Tribulus terrestris
Opis:
Background and Aim: Fibrosis, which develops during the progression of liver damage, is the previous stage of cirrhosis. Carbon tetrachloride is one of the most commonly used hepatic toxins in experimental animal models of liver fibrosis. It was investigated the hepatoprotective effects of Tribulus terrestris, Ashwagandha and N-acetylcysteine in an experimental model of liver fibrosis induced by carbon tetrachloride in this study. Methods: Fifty Wistar rats were divided into five groups of 10 each, as follows: 1) control, 2) carbon tetrachloride, 3) carbon tetrachloride plus N-acetylcysteine, 4) carbon tetrachloride plus T. terrestris, and 5) carbon tetrachloride plus Ashwagandha group. At the end of 6 weeks, the rats were sacrificed, and serum and tissue samples were collected. Aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, malondialdehyde, NF-κB, collagen 1, nuclear factor erythroid-2-related factor 2, tumor necrosis factor-α were analyzed, and histopathological evaluation was performed. Results: There were no significant differences in serum aspartate aminotransferase and alanine aminotransferase levels of the N-acetylcysteine-treated group versus those in the T. terrestris- and Ashwagandha-treated groups (p>0.05). Liver malondialdehyde levels were lower in the N-acetylcysteine-, T. terrestris- and Ashwagandha-treated groups than in the carbon tetrachloride-administered group (p<0.001). There were differences between groups in NF-κB, collagen 1, nuclear factor erythroid-2-related factor 2 and tumor necrosis factor-α levels (p<0.05). Conclusions: In conclusion, T. terrestris, Ashwagandha and N-acetylcysteine had protective effects on the liver in this experimental fibrosis model. T.Terrestris was a little more effective than Ashwagandha in combating liver fibrosis.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 5; 805-813
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Novel Aryl/Alkyl Azole Derivates as an anti-nociceptive and anti-inflammatory drug candidates
Autorzy:
Kaya-Yasar, Yesim
Barut, Elif N.
Engin, Seckin
Dogan, Inci S.
Sezen, Feride S.
Powiązania:
https://bibliotekanauki.pl/articles/895330.pdf
Data publikacji:
2020-04-29
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
pain
inflammation
aryl/alkyl azole
COX-LOX
formalin-induced hind paw edema test
hot plate test
Opis:
Novel aryl/alkyl azole derivative compounds C1 and C2 were screened for in vivo anti-nociceptive and anti-inflammatory activities by using the hot plate test and formalin-induced hind paw edema test, respectively. Ability of these compounds to inhibit cyclooxygenase-1/2 (COX-1/2) and 5/15-lipoxygenase (5/15-LOX) were evaluated in vitro by using a colorimetric method. C1 (30 and 50 mg/kg, i.p.) and C2 (3 and 30 mg/kg, i.p.) increased the latency to withdrawal in the hot plate test, indicating an anti-nociceptive activity. C1(30 and 50 mg/kg) and C2 (3,30 and 50 mg) were able to decrease formalin-induced edema, indicating their anti-inflammatory properties. C1 and C2 exhibited inhibitory effects on the activity of COX(1-2) and 15-LOX. However, neither C1 nor C2 showed an inhibitory effect on 5-LOX. This study demonstrates that C1 and C2 have anti-nociceptive and anti-inflammatory activities, that is partially mediated by inhibition of COX and LOX enzymes. Our results suggest that C1 and C2, novel aryl/alkyl azole compounds, could serve as lead compounds to develop novel therapeutic options for the treatment of pain and inflammation.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2020, 77, 2; 289-294
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies